Background
==========

Iron deficiency anemia (IDA) is a major public health problem all over the world \[[@b1-medscimonit-24-6449]\]. Iron (Fe) fortification through diet can be an effective strategy for cure and prevention of IDA \[[@b2-medscimonit-24-6449],[@b3-medscimonit-24-6449]\], but food fortification with Fe is challenging. Water-soluble Fe fortificants with high bioavailability, such as ferrous sulfate (FeSO~4~) and sodium iron ethylene diamine tetra acetic acid (EDTA), often cause adverse sensory changes in foods \[[@b4-medscimonit-24-6449]--[@b6-medscimonit-24-6449]\]. Poorly soluble Fe fortificants such as ferrous fumarate and ferric pyrophosphate tend to have fewer sensory changes but have low bioavailability or aggregate in beverages \[[@b7-medscimonit-24-6449],[@b8-medscimonit-24-6449]\]. Therefore, developing new Fe fortificants with both high bioavailability and negligible food sensory changes for IDA is urgent.

Recently, iron nanoparticles have shown exciting potential for novel iron fortificants with high bioavailability and low reactivity compared with current sodium iron EDTA and FeSO~4~ \[[@b9-medscimonit-24-6449],[@b10-medscimonit-24-6449]\]. However, iron nanoparticles with limited colloidal stability can be easily oxidized and aggregated rapidly in the solution, causing concern regarding biosafety \[[@b9-medscimonit-24-6449],[@b11-medscimonit-24-6449]--[@b13-medscimonit-24-6449]\]. As a result, facile fabrication of iron nanoparticles with good solubility, high bioavailability, and acceptable biocompatibility remains challenging.

Protein-mediated fabrication of functional nanomaterials with desirable properties has attracted research attention due to its simple procedure, mild synthesis conditions, and good reproducibility \[[@b14-medscimonit-24-6449]\]. Various nanostructures with fascinating features have been fabricated by using proteins as stabilized agents via mimicking biomineralization processes \[[@b15-medscimonit-24-6449],[@b16-medscimonit-24-6449]\]. Albumin is often chosen as a biocompatible template for the synthesis of water-soluble nanoparticles due to its abundant hydrophilic functional groups, such as thiol, amine, and carboxyl groups \[[@b17-medscimonit-24-6449]\]. Albumin has been approved by the U.S. Food and Drug Administration (FDA) for clinical use, showing reliable biosafety. Therefore, it is very attractive to develop albumin-directed Fe nanoparticles with good solubility and biocompatibility for Fe fortification through the facile biomineralization-mimicking method.

Here, we present novel albumin-protected Fe nanoparticles with good solubility and inherent biocompatibility for IDA treatment. We also compared the bioavailability of Fe nanoparticles and FeSO~4~. Systematic results demonstrated that the proposed albumin-protected Fe nanoparticles have the same high bioavailability as FeSO~4~, showing good potential for clinical translation.

Material and Methods
====================

Materials and reagents
----------------------

Double-distilled water was used throughout this work. Bovine serum albumin (BSA) and methyl thiazolyl tetrazolium (MTT) were bought from Aladdin Reagent Co., Ltd. (Shanghai, China). FeCl~3~·6H~2~O, FeSO~4~·H~2~O, and NaBH~4~ were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Synthesis of BSA-Fe nanoparticles
---------------------------------

BSA-Fe nanoparticles were fabricated by *in situ* chemical reduction of FeCl~3~·6H~2~O in BSA \[[@b10-medscimonit-24-6449]\]. Briefly, 250 mg of BSA was mixed with 0.1 M FeCl~3~·6H~2~O in 10 mL of water. Fe(III) ions bound to the functional groups of BSA were then chemically reduced to Fe by adding NaBH~4~ (0.2 M). After reacting for 30 min, the final product was obtained through dialysis and freeze-drying. The lyophilized powder of BSA-Fe nanoparticles was stored at −4°C until further use.

Characterizations
-----------------

The morphology and size of BSA-Fe nanoparticles were characterized via high-resolution transmission electron microscopy (HRTEM, Philips, Holland). Fourier trans-form infrared (FT-IR) spectra of BSA and BSA-Fe were recorded with a spectrometer (Nicolet, USA) ranging from 650 to 4000 cm^−1^. The hydrodynamic size of the BSA and BSA-Fe nanoparticles was measured on a Malvern Zetasizer instrument (Nano series ZS, UK). The Fe content in BSA-Fe was determined through atomic absorption spectroscopy (AAS).

*In vitro* solubility
---------------------

The *in vitro* solubility of BSA-Fe and FeSO~4~ was tested as follows: A compound containing 20 mg Fe was dissolved in 250 mL of hydrochloric acid (0.1 M, pH 1). The mixture was then placed on a shaker at 200 rpm at 37°C. The percentage of dissolved Fe element was measured after 5, 15, 30, 45, and 60 min. The Fe content of the supernatant solution after centrifugation was measured by AAS.

Cell viability assay
--------------------

4T1 cells (a mouse-derived breast cancer cell line) and 3T3 cells (a mouse embryonic fibroblast cell line) were regularly cultured in RPMI-1640 (Hyclone, USA) supplemented with 10% FBS (Gibco, USA) and 1% penicillin-streptomycin (Hyclone, USA) in an atmosphere of 5% CO~2~ at 37°C. Cell viability of BSA-Fe was measured through MTT assay in 4T1 cells and 3T3 cells. 4T1 cells and 3T3 cells were seeded in a 96-well plate at a density of 8×10^3^ cells/well in 200 μL of fresh culture medium at 37°C and 5% CO~2~. After 24-h incubation, the stale medium in each well was replaced with 200 μL of fresh medium containing different concentrations of BSA-Fe nanoparticles. After another 24-h incubation, the cells were incubated with fresh medium containing 10 μL of MTT (5 mg mL^−1^). Four hours later, the supernatant in each well was replaced with 150 μL of DMSO. Finally, the cell viabilities were calculated depending on the absorbance values at 490 nm of each well.

The bioavailability and biocompatibility *in vivo*
--------------------------------------------------

All the animal experiments throughout this work were approved by the Animal Care and Use Committee of our institution. The bioavailability of BSA-Fe nanoparticles was investigated by the hemoglobin (Hb) repletion method. Sprague-Dawley (SD) rats (n=50, 21±2 days old) were housed and fed individually in stainless steel cages. The rats were kept with a 12-h light/dark cycle at 24°C. The anemic rat model was built according to a previous report by an Fe-deficient (Fe-def) diet (2.5 mg Fe/kg) for 14 d. After the depletion period, rats were randomly assigned to 5 groups. The rats in each group consumed the same Fe-def diet with different fortificants at 2 levels (FeSO~4~, 10 or 20 mg/Kg diet; BSA-Fe, 10 or 20 mg/Kg diet), or no added Fe (Fe-def, 2.5 mg Fe/kg diet) for 10 d. In the meantime, 10 rats (35 days old) fed normal diets were used as the normal control group. During the 10-d period, these rats were weighed every 2 days. At the tenth day, the blood samples of these rats were collected for assessment of Hb, red blood cells count (RBC), and other biochemical indicators (e.g., alanine aminotransferase, ALT; aspartate aminotransferase, AST; creatinine CREA; urea). The vital organs (heart, liver, spleen, lung, and kidney) of these rats were extracted for comparisons in the histological assessment.

Statistical analysis
--------------------

All quantitative data are presented as means ±SEM. Significance differences between groups were determined by the 2-tailed *t* test. All statistical analyses were calculated with SPSS version 15. *P*\<0.05 was considered significant.

Results
=======

Synthesis and characterizations of BSA-Fe nanoparticles
-------------------------------------------------------

Good water solubility is important for Fe nanoparticles to prevent strong colloidal aggregation when used in drinks and foods \[[@b18-medscimonit-24-6449],[@b19-medscimonit-24-6449]\]. In this work, the Fe nanoparticles were fabricated through a one-pot facile reduction process under the protection of BSA ([Figure 1A](#f1-medscimonit-24-6449){ref-type="fig"}). When FeCl~3~·6H~2~O is mixed with BSA by stirring, Fe (III) ions can bind strongly onto BSA due to the high affinity between Fe element and functional chemical groups (e.g., carboxy group, amino group, and sulfhydryl group) of BSA. After adding NaBH~4~, iron ions are converted immediately into Fe nanoparticles by the strong reducing agent. Thanks to the protection of BSA as the reaction template, the size of Fe nanoparticles was under control. As shown in [Figure 1B](#f1-medscimonit-24-6449){ref-type="fig"}, the HRTEM image of BSA-Fe nanoparticles showed a round geometry with a super-tiny size of only \<10 nm. FT-IR spectra showed the presence of BSA in obtained BSA-Fe nanoparticles ([Figure 1C](#f1-medscimonit-24-6449){ref-type="fig"}). BSA has perfect water solubility; therefore, BSA-protected Fe nanoparticles have a hydrodynamic size of only about 10 nm ([Figure 1D](#f1-medscimonit-24-6449){ref-type="fig"}). The hydrodynamic size of BSA-Fe nanoparticles had only negligible change during an observation period as long as 30 days ([Figure 1E](#f1-medscimonit-24-6449){ref-type="fig"}), exhibiting good water solubility and colloidal stability. To further mimic the actual gastric acid environment when the Fe fortificants are orally administrated, the solubility of BSA-Fe nanoparticles was investigated at pH 1. As shown in [Figure 1F](#f1-medscimonit-24-6449){ref-type="fig"}, BSA-Fe nanoparticles and FeSO~4~ dissolved well at pH 1. Interestingly, the BSA-Fe nanoparticles were more soluble than FeSO~4~ after 5 min, but there was no significant difference between the solubility of the BSA-Fe nanoparticles and FeSO~4~ at the other time points. Our results show that the BSA-Fe nanoparticles fabricated through the facile one-pot reducing method have good water solubility, even better than that of FeSO~4~.

The cytotoxicity of BSA-Fe nanoparticles
----------------------------------------

The cytotoxicity of the BSA-Fe nanoparticles was estimated through the cellular MTT assay with 4T1 cells and 3T3 cells. As shown in [Figure 2](#f2-medscimonit-24-6449){ref-type="fig"}, BSA-Fe nanoparticles with different concentrations ranging from 0 to 500 μg/mL resulted in negligible decrease in cell viability in 4T1 cells and 3T3 cells. Even at concentrations as high as 500 μg/mL, the cell viability was still above 80%. Low cytotoxicity is the essential requirement for BSA-Fe nanoparticles for further *in vivo* applications.

The bioavailability and biocompatibility of BSA-Fe nanoparticles *in vivo*
--------------------------------------------------------------------------

The bioavailability of BSA-Fe nanoparticles was investigated by the Hb repletion method \[[@b20-medscimonit-24-6449]\]. As shown in [Figure 3](#f3-medscimonit-24-6449){ref-type="fig"}, the anemia rat model established through the Fe-deficiency diet showed obvious decrease in Hb and RBC levels compared with the normal control group. The Fe fortification of BSA-Fe nanoparticles and FeSO~4~ can significantly elevate the Hb level of anemia rats, especially with higher Fe content ([Figure 3A](#f3-medscimonit-24-6449){ref-type="fig"}), and there was no significant difference between BSA-Fe nanoparticles and FeSO~4~ at the same dosage of Fe. Even low Fe fortification (10 mg/Kg) made no significant contribution to the RBC enhancement; RBC levels of anemia rats obviously increased when given higher dosage of BSA-Fe nanoparticles and FeSO~4~ and no significant difference was observed between them ([Figure 3B](#f3-medscimonit-24-6449){ref-type="fig"}). In addition, the body weights of anemia rats also remarkably increase during the treatments, especially with higher Fe fortification ([Figure 4A](#f4-medscimonit-24-6449){ref-type="fig"}). All these results demonstrate that the proposed BSA-Fe nanoparticles have bioavailability comparable to that of the most widely used Fe fortificants of FeSO~4~.

Besides good bioavailability, biosafety is another important concern for further clinical translations. After Fe fortification, the vital organs of rats were extracted. The histopathological results showed no obvious histological changes in the susceptible organs (heart, liver, spleen, lung, and kidney) for 10 d after administrations of BSA-Fe nanoparticles and FeSO~4~ when compared with the normal control group ([Figure 4B](#f4-medscimonit-24-6449){ref-type="fig"}). Blood biochemical analysis indicated that administration of BSA-Fe nanoparticles did not damage liver or kidney function ([Figure 5](#f5-medscimonit-24-6449){ref-type="fig"}). These results demonstrate the good biocompatibility of BSA-Fe nanoparticles for further clinical use.

Discussion
==========

Iron deficiency is one of the highest risk factors for death and disability all over the world \[[@b1-medscimonit-24-6449]\]. Targeted iron supplementation or food iron fortification is a reliable way to correct iron deficiency in populations \[[@b21-medscimonit-24-6449]\]. Although FeSO~4~ with high bioavailability is widely used as effective Fe fortificants, it is still criticized for causing adverse sensory changes in foods \[[@b22-medscimonit-24-6449]\]. Recently, ferrous nano-compounds such as ferric phosphate (FePO~4~) and Fe nanoparticles \[[@b9-medscimonit-24-6449],[@b10-medscimonit-24-6449],[@b20-medscimonit-24-6449]\] have attracted increased attention due to their good potential as substitutes of FeSO~4~.

For clinical translation of ferrous nano-compounds, several essential requirements must be met, such as simple production, comparative bioavailability, and good biocompatibility \[[@b23-medscimonit-24-6449],[@b24-medscimonit-24-6449]\]. In the present work, BSA-Fe nanoparticles were fabricated through a one-pot facile reducing method within just 30 min. The whole procedure was conducted at room temperature without any other harsh conditions like starvation, high temperature, or high pressure. This simple, mild, and fast fabrication makes BSA-Fe nanoparticles suitable for further industrial production. Data show that BSA-Fe nanoparticles have good water solubility and stability, even in acidic environments. The comparative bioavailability with FeSO~4~ can be also found in BSA-Fe nanoparticles. In addition, BSA-Fe nanoparticles showed remarkable biocompatibility both *in vitro* and *in vivo*. The BSA-Fe nanoparticles proposed in this work have a good potential for clinical translation.

Conclusions
===========

We fabricated the water-soluble BSA-Fe nanoparticles using a one-pot facile reducing method. It has bioavailability comparable to that of FeSO~4~ and acceptable biocompatibility, showing good potential for further clinical translations.
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